The new drug application provides for the use of Abacavir sulfate 60mg tablets in combination with other antiretrovirals for use in pediatric patients for the treatment of HIV-1 infection.
The company had earlier received tentative approvals for Abacavir sulfate tablets 300mg and Abacavir sulfate oral solution 20mg/mL.